David A. Spiegel, M.D. PH.D.

David is the CEO and co-founder of Kleo Pharmaceuticals. He is a Professor of Chemistry and Pharmacology at Yale University where he heads the Spiegel Research Group. He has co-authored over 40 peer-reviewed publications and is an inventor with over a dozen patents, including those that underlie Kleo's ARM and SyAM platforms. He has been recognized with various awards and honors, including the NIH Director's New Innovators Award, the Ellison Medical Foundation New Scholar Award in Aging Research, the Bill and Melinda Gates Foundation Grand Challenges Explorations Award, an Alfred P. Sloan Foundation Fellowship, an Arthur C. Cope Early Career Scholars Award, and others.


Joseph F, Grosso, PH.D.

Joseph is the CSO of Kleo Pharmaceuticals. Prior to joining Kleo, he served as Director of Immuno-Oncology at Celgene and focused on the clinical development of immuno-oncology platforms, including CAR-T cells. Prior to Celgene, Joe was at Bristol-Myers Squibb, where he served on the nivolumab (Opdivo®) clinical development team and focused on designing biomarker-intensive clinical trials in novel oncology indications, leading the biomarker effort for nivolumab (Opdivo®) and other IO assets across multiple solid and hematological indications. He received his B.S. in Microbiology and Immunology at the University of Rochester and earned his Ph.D. in Microbiology and Immunology from University of Miami. 


Roy Prieb

Roy Prieb is the COO/CFO and co-founder of Kleo Pharmaceuticals. He is a technology entrepreneur with over 15 years experience in business strategy, development, and operations. Roy has helped launch, fund, and grow several digital media ventures including Saaspire, Kellogg Media Group,, and Earlier in his career, he was a consultant with The Boston Consulting Group. He received his B.A. from Harvard University and M.B.A. from Wharton Business School.